Search

    Language Settings
    Select Website Language

    GDPR Compliance

    We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

    BijnorNews
    Bijnor news

    Ajanta Pharma Q2 Review: Stock Rally Limits Upside Despite Robust Performance, Says Systematix

    4 days ago

    The brokerage incorporates Ajanta Pharma's quarterly performance into its estimates and expect India to remain a key growth driver, supported by sustained outperformance against IPM, while factoring in normalisation in Africa institutional business.
    Click here to Read More
    Previous Article
    Ramayana: Ranbir Kapoor Compares Pushpak Viman To Elon Musk's Newly Launched 'Flying Car'
    Next Article
    Inside Shah Rukh Khan’s Rs 10,000-Crore Net Worth: Mannat, Luxury Cars, Private Jet, KKR

    Related Business Updates:

    Are you sure? You want to delete this comment..! Remove Cancel

    Comments (0)

      Leave a comment